# 环吡酮市场 > 环吡酮市场研究报告按应用（股癣、足癣、甲癣、体癣、花斑癣）、按药物类型（乳膏、凝胶、指甲油、溶液、洗发水）、按形式（外用、口服）、按给药途径（外用、口服）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.89% - **2024:** $ 0.48 Billion - **2025:** $ 0.51 Billion - **2035:** $ 0.82 Billion - **Key Players:** Bayer AG (DE), Galderma S.A. (CH), Mylan N.V. (NL), Perrigo Company plc (IE), Sandoz International GmbH (CH), Teva Pharmaceutical Industries Ltd. (IL), Valeant Pharmaceuticals International, Inc. (CA), Zydus Cadila (IN) **Report ID:** MRFR/HC/28447-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Kinjoll Dey · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/ciclopirox-market-30191 --- ## Market Summary ## **Ciclopirox Market Overview** As per MRFR analysis, the Ciclopirox Market Size was estimated at 0.48 (USD Billion) in 2024. The Ciclopirox Market Industry is expected to grow from 0.51 (USD Billion) in 2025 to 0.78 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.89% during the forecast period (2025 - 2034). **Key Ciclopirox Market Trends Highlighted** Ciclopirox is an antifungal medication used to treat a variety of skin infections. It is available in both topical and oral forms. The topical form is applied directly to the affected area, while the oral form is taken by mouth. Ciclopirox works by inhibiting the growth of fungi. Key market drivers for ciclopirox include the rising prevalence of fungal infections and the increasing demand for effective antifungal treatments. Opportunities to be explored in the ciclopirox market include the development of new and improved formulations and the expansion into new markets. In recent times, the market has witnessed significant growth due to the increasing awareness of fungal infections and the availability of effective treatment options. Key trends in the ciclopirox market include the growing popularity of topical formulations, the increasing use of oral formulations for systemic infections, and the development of new drug delivery systems. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Ciclopirox Market Drivers** Rising Prevalence of Fungal Infections Fungal infections are a major global health concern, affecting millions of people worldwide. The rising prevalence of these infections is primarily due to factors such as increasing antibiotic use, weakened immune systems, and the emergence of new and resistant fungal strains. Ciclopirox, with its broad-spectrum antifungal activity and minimal side effects, is a valuable treatment option for various fungal infections, including onychomycosis, tinea pedis, and tinea corporis. The growing incidence of these infections is expected to drive the demand for ciclopirox in the coming years. Increasing Awareness and Diagnosis of Fungal Infections Traditionally, fungal infections have been underdiagnosed and undertreated due to a lack of awareness and limited access to diagnostic tools. However, recent advances in diagnostic techniques, such as PCR and culture-based methods, have improved the accuracy and speed of fungal identification. This increased awareness and improved diagnosis are leading to a greater number of patients being diagnosed with fungal infections, subsequently driving the demand for effective treatment options like ciclopirox. Technological Advancements in Drug Delivery Ongoing advancements in drug delivery systems are enhancing the efficacy and convenience of ciclopirox treatment. Novel formulations, such as nanocarriers, liposomes, and micelles, are being developed to improve drug penetration, reduce side effects, and enhance patient compliance. These advancements are expected to expand the application of ciclopirox in the treatment of various fungal infections and contribute to the growth of the Global Ciclopirox Market Industry. **Ciclopirox Market Segment Insights:** **Ciclopirox Market Application Insights** Application Segment Insights and Overview The application segment plays a crucial role in shaping the dynamics of the Global Ciclopirox Market. Among the various applications, Tinea Cruris (jock itch), Tinea Pedis (athlete's foot), Tinea Unguium (onychomycosis), Tinea Corporis (ringworm), and Tinea Versicolor (pityriasis versicolor) hold significant market shares. Tinea Cruris, commonly known as jock itch, is a fungal infection that affects the groin area. The Global Ciclopirox Market for Tinea Cruris treatment is projected to witness substantial growth owing to the rising prevalence of the infection, particularly among athletes and individuals engaged in physical activities. Tinea Pedis, also known as athlete's foot, is another prevalent fungal infection that affects the feet. The Global Ciclopirox Market for Tinea Pedis treatment is anticipated to expand at a steady pace, driven by increasing awareness about foot hygiene and the availability of effective topical treatments. Tinea Unguium, commonly referred to as onychomycosis, is a fungal infection of the toenails or fingernails. The Global Ciclopirox Market for Tinea Unguium treatment is expected to exhibit moderate growth, primarily due to the chronic nature of the infection and the need for prolonged treatment regimens. Tinea Corporis, commonly known as ringworm, is a fungal infection that affects the skin on various parts of the body. The Global Ciclopirox Market for Tinea Corporis treatment is projected to grow at a moderate pace, driven by the increasing incidence of skin infections and the efficacy of ciclopirox in treating these conditions. Tinea Versicolor, also known as pityriasis versicolor, is a common fungal infection of the skin that causes discolored patches. The Global Ciclopirox Market for Tinea Versicolor treatment is anticipated to witness steady growth, supported by the increasing prevalence of the infection and the availability of effective topical treatments. Overall, the application segment of the Global Ciclopirox Market is highly competitive, with several players offering a wide range of products. The market is expected to continue to grow in the coming years, driven by the rising prevalence of fungal infections and the increasing demand for effective treatments. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Ciclopirox Market Drug Type Insights** The Global Ciclopirox Market is segmented by Drug Type into Cream, Gel, Nail Polish, Solution, and Shampoo. The Cream segment held the largest market share in 2023, accounting for around 40% of the Global Ciclopirox Market revenue. The Gel segment is projected to be the fastest-growing segment during the forecast period, with a CAGR of 5.5% from 2024 to 2032. The growth of the Gel segment can be attributed to the increasing prevalence of fungal infections and the ease of application of gels. The Solution segment is also expected to witness significant growth during the forecast period, with a CAGR of 4.8%. The growth of the Solution segment can be attributed to the increasing demand for non-prescription topical antifungal solutions for the treatment of mild fungal infections. The Nail Polish segment is expected to hold a steady market share during the forecast period, with a CAGR of 4.0%. The Shampoo segment is expected to have a CAGR of 3.5% during the forecast period. **Ciclopirox Market Form Insights** The Global Ciclopirox Market is segmented by form into topical and oral. Topical Ciclopirox is projected to hold a significant market share due to its extensive use in treating fungal skin infections. In 2023, the topical segment held a dominant market share of around 80%, and it is anticipated to maintain its dominance throughout the forecast period. The growth of the topical segment can be attributed to the ease of application, fewer side effects, and widespread availability of topical formulations. On the other hand, the oral segment is expected to witness a steady growth rate during the forecast period. Oral Ciclopirox is primarily used for treating systemic fungal infections and is often preferred when topical treatment is not effective or feasible. **Ciclopirox Market Route of Administration Insights** The Global Ciclopirox Market is segmented based on the Route of Administration into Topical and Oral. The Topical segment held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period. The growth of the Topical segment can be attributed to the increasing prevalence of fungal infections, such as athlete's foot and ringworm, which are commonly treated with topical ciclopirox. The Oral segment is expected to witness a significant growth rate during the forecast period due to the rising incidence of systemic fungal infections, such as candidiasis and aspergillosis, which require oral administration of ciclopirox. **Ciclopirox Market Regional Insights** Regionally, North America dominated the market, accounting for a significant share of the global revenue in 2023. Europe is anticipated to follow North America, with a considerable market size. APAC is projected to witness the fastest growth rate during the forecast period, driven by increasing demand from emerging economies such as China and India. South America and MEA are expected to contribute steadily to the overall market growth. The market growth is attributed to the rising prevalence of fungal infections, increasing awareness about ciclopirox, and the launch of new products. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Ciclopirox Market Key Players and Competitive Insights:** Major players in the Ciclopirox Market industry are constantly engaging in research and development to enhance their product offerings and gain a competitive edge. Leading Ciclopirox Market players are focusing on developing innovative products that meet the evolving needs of customers. The Ciclopirox Market development includes the introduction of new products, the expansion of existing product lines, and the acquisition of other companies. The competitive landscape of the Ciclopirox Market is expected to remain dynamic over the forecast period, with major players continuing to compete on factors such as product quality, innovation, and cost-effectiveness. A leading company in the Global Ciclopirox Market is Bausch Health Companies Inc. The company's strong brand recognition, extensive distribution network, and focus on research and development have contributed to its success in the market. Bausch Health Companies Inc. offers a range of Ciclopirox products, including topical solutions, creams, and ointments. The company's products are marketed under various brand names, such as Loprox and Penlac. Bausch Health Companies Inc. has a strong presence in North America and Europe, and the company is also expanding its presence in emerging markets. Another major player in the Global Ciclopirox Market is Taro Pharmaceutical Industries Ltd. The company's strengths include its low-cost manufacturing capabilities, its strong product portfolio, and its extensive distribution network. Taro Pharmaceutical Industries Ltd. offers a range of Ciclopirox products, including topical solutions, creams, and ointments. The company's products are marketed under various brand names, such as Ciclodan and Ciclopirox-T. Taro Pharmaceutical Industries Ltd. has a strong presence in North America and Europe, and the company is also expanding its presence in emerging markets. **Key Companies in the Ciclopirox Market Include:** **Ciclopirox Market Industry Developments** _The increasing prevalence of fungal infections, rising awareness about Ciclopirox, and the launch of new products are key factors driving market growth._ _Recent developments include the approval of Luzu's topical Ciclopirox solution for the treatment of onychomycosis in 2023 and the acquisition of Taro Pharmaceuticals by Hikma Pharmaceuticals in 2022, strengthening Hikma's position in the antifungal market._ _The market is expected to witness continued growth due to the increasing demand for effective antifungal treatments and the development of new formulations and delivery systems._ **Ciclopirox Market Segmentation Insights** ## Market Drivers ### 制药研究的进展 制药研究与开发的创新正在显著影响环吡酮市场。最近的研究集中在提高现有抗真菌药物的疗效和安全性，包括环吡酮市场。新型制剂和给药系统的引入可能会改善患者的依从性和治疗结果。此外，环吡酮市场可能会看到结合疗法的增加，这些疗法利用多种抗真菌药物的优势。数据表明，结合疗法可以提高对耐药真菌株的疗效，这一趋势得到了支持。随着研究的不断发展，环吡酮市场可能会扩大，推动因素是新型和改进的治疗选择的引入。 ### 电子商务平台的扩展 电子商务平台的普及正在改变消费者获取医疗产品的方式，包括环吡酮醇市场。在线零售提供了便利性和可及性，使消费者能够在家中舒适地购买抗真菌治疗。这种向数字渠道的转变在消费者对在线购物偏好日益增加的背景下尤为相关。市场分析表明，医疗产品的电子商务销售，包括环吡酮醇市场，正在上升，推动因素包括竞争性定价和更广泛的产品可用性。随着电子商务的持续扩展，环吡酮醇市场可能会受益于增强的分销渠道，最终导致销售和市场渗透的增加。 ### 皮肤健康意识的提升 对皮肤健康和卫生的日益关注正在成为环吡酮市场的重要驱动力。消费者越来越意识到保持皮肤健康的重要性，特别是在预防真菌感染方面。这一趋势反映在对抗真菌产品的需求不断增长，包括那些含有环吡酮的产品。市场数据显示，消费者正在积极寻找有效的皮肤相关问题解决方案，这可能导致基于环吡酮的治疗产品销售的增加。此外，随着教育活动推广抗真菌治疗在维护皮肤健康方面的好处，环吡酮市场可能会看到增长。随着意识的不断提高，市场可能会扩大，受到消费者对有效和可靠产品需求的推动。 ### 真菌感染的日益普遍 真菌感染的发病率上升，特别是在免疫系统受损的个体中，似乎是环吡酮市场的主要驱动因素。报告显示，糖尿病和HIV/AIDS等疾病导致这些感染的易感性增加。因此，对有效抗真菌治疗的需求，包括环吡酮市场，可能会加剧。随着医疗服务提供者寻求可靠的解决方案来对抗这些感染，环吡酮市场预计将经历增长。此外，公众对真菌感染的认识不断提高，可能导致更早的诊断和治疗，进一步推动市场增长。因此，环吡酮市场有望从这一趋势中受益，处方和非处方产品的销售都有可能增加。 ### 抗真菌产品的监管支持 监管机构越来越认识到有效抗真菌治疗的必要性，这可能会促进环吡酮市场的发展。最近旨在加快抗真菌药物审批流程的举措可能会促进环吡酮市场及类似产品的更快进入。这种监管支持至关重要，尤其是在抵抗性真菌感染威胁日益增长的背景下。环吡酮市场可能会受益于简化的审批途径，使制造商能够更高效地将其产品推向市场。此外，监管框架中对患者安全性和疗效的重视可能会鼓励创新配方的发展，从而增强整体市场格局。 ## Future Outlook 环吡酮市场预计将在2024年至2035年间以4.89%的年均增长率增长，主要受抗真菌治疗需求增加和皮肤科应用扩展的推动。 **New opportunities:** - 与环吡酮市场的联合疗法开发以提高疗效。 到2035年，Ciclopirox市场预计将巩固其作为抗真菌治疗关键参与者的地位。 ## Segment Insights ### 按应用：足癣（最大）与甲癣（生长最快） 在环吡酮市场中，足癣（Tinea Pedis），通常被称为运动员脚，是最大的细分市场，主导着应用类别。这种情况影响了相当大一部分人群，导致了高度的意识，进而对有效治疗方案的强劲需求。紧随其后的是甲癣（Tinea Unguium），或称为甲真菌病，因其普遍性和严重性而越来越受到关注，成为制药进步的一个吸引焦点。 足癣（主导）与甲癣（新兴） 足癣是运动员脚气的病因，是环吡酮醇市场中一个成熟的细分领域。其主导地位源于广泛的发生率以及运动员和暴露于公共环境中的个体频繁需要干预。另一方面，甲癣正在迅速崛起，受到公众意识增强和老龄化人口的推动，导致病例激增。该细分市场的快速增长得益于治疗选择的进步以及消费者寻求指甲真菌感染解决方案的意愿日益增强。 ### 按药物类型：乳膏（最大）与凝胶（增长最快） 在环吡酮市场中，药物类型细分主要由乳膏主导，因其易于使用和有效的效果而受到消费者青睐。紧随其后的是凝胶制剂，尽管市场份额较小，但由于其快速干燥的特性和非油腻的效果，正在获得关注。其他形式，如指甲油、溶液和洗发水，虽然对市场有贡献，但份额显著较低，表明消费者对乳膏和凝胶选项有明显偏好。 环吡酮市场药物类型细分中的增长趋势突显出对凝胶制剂的转变。这是由于消费者寻求创新和用户友好的真菌感染治疗方案。强调凝胶益处的营销策略，包括更快的吸收时间和适合活跃生活方式的便利性，正在推动其在市场上的快速扩张。相比之下，尽管乳膏仍然是许多人的首选，但它面临着来自迎合现代消费者需求的新兴产品的日益竞争。 奶油（主导）与凝胶（新兴） 在环吡酮市场中，乳膏已确立为主导药物类型，以其在治疗真菌感染方面的有效性而受到推崇。它提供了一种消费者多年来依赖的熟悉且值得信赖的形式，通常呈现出粘稠且舒缓的涂抹效果，吸引那些寻求全面护肤的人。另一方面，凝胶代表了一种新兴的替代品，以其创新的配方吸引消费者。凝胶产品因其轻盈的质地和快速干燥的特性而受到赞誉，使其成为适合忙碌人士的理想选择。对凝胶日益增长的需求表明，消费者偏好向更现代化和高效的治疗选择转变，使凝胶在市场中成为一个重要的竞争者。 ### 按形式：局部（最大）与口服（增长最快） 在环吡酮市场中，局部用药细分市场作为按形式划分的最大细分市场，占据了显著的市场份额。这种治疗形式因其直接应用而受到青睐，导致了针对性的疗效和减少的全身暴露，使其在患者和医疗提供者中尤其受欢迎。相反，口服细分市场虽然较小，但被认为是增长最快的，受到越来越多患者对提供更方便和合规的全身治疗的偏好推动，寻求有效的真菌感染解决方案。 形式：局部（主导）与口服（新兴） 外用形式的环吡酮醇市场以其易于应用和快速作用为特征，使其成为消费者和医疗专业人员的主导选择。该细分市场受益于强大的临床证据基础，支持其在治疗各种皮肤病方面的有效性。相比之下，口服形式在市场上呈现出新兴机会，吸引那些偏好系统治疗的患者。该细分市场的增长受到配方技术进步和对便捷治疗选择需求的推动，这可能进一步推动其在市场中的渗透。 ### 按给药途径：局部（最大）与口服（增长最快） 在环吡酮市场中，给药途径在影响消费者偏好和治疗结果方面发挥着至关重要的作用。局部应用仍然是最大的细分市场，由于其在局部治疗真菌感染方面的有效性，捕获了可观的市场份额。患者和医疗提供者更喜欢局部制剂，因为它们使用方便，能够直接作用于感染部位，并且与口服给药相比，系统性副作用较少。然而，口服途径正在迅速崛起，主要是由于对广泛真菌感染的系统性治疗的需求，而局部溶液可能无法满足这一需求。 环吡酮市场：局部（主导）与口服（新兴） 局部环吡酮市场的制剂主导市场，主要用于治疗局部皮肤癣菌感染和抗真菌治疗。其制剂，如乳膏和清漆，因其靶向作用和最小的不良反应而受到青睐，成为许多患者的首选。另一方面，口服环吡酮市场细分被归类为新兴市场，因其在治疗系统性感染方面的潜力而见证了显著增长。这一日益增长的采用归因于医疗提供者对口服制剂在提供全面治疗选项方面的有效性日益增强的认识，这种治疗选项能够解决更广泛的真菌感染。随着市场的发展，这两个细分市场将继续在塑造治疗策略中发挥关键作用。 ## Regional Market Share Analysis ### 北美：创新市场的领导者 北美是环吡酮市场最大的市场，约占全球市场份额的45%。该地区的增长受到真菌感染发生率增加、对皮肤病状况的认识提高以及支持性监管框架的推动。FDA的批准流程促进了创新治疗的更快获取，进一步推动了环吡酮市场产品的需求。 美国和加拿大是该市场的领先国家，拜耳公司和Teva制药工业有限公司等主要制药公司积极参与。竞争格局由一系列成熟企业和新兴公司组成，确保消费者可以获得多样化的环吡酮市场配方。强大的分销网络的存在增强了市场渗透率和可及性。 ### 欧洲：监管支持与增长 欧洲是环吡酮市场的第二大市场，约占全球市场份额的30%。该地区受益于严格的监管标准，确保产品的安全性和有效性，增强了消费者信心。医疗保健支出的增加和老年人口的增长是推动对抗真菌治疗（包括环吡酮市场）需求上升的关键因素。 欧洲的主要国家包括德国、法国和英国，主要参与者如Galderma S.A.和Mylan N.V.在市场上占据重要地位。竞争格局强劲，地方和国际公司争相争夺市场份额。欧洲药品管理局致力于促进皮肤病治疗的创新，进一步增强了市场的增长潜力。 ### 亚太地区：新兴市场潜力 亚太地区在环吡酮市场上正经历显著增长，推动因素包括对皮肤健康的认识提高和可支配收入的增加。该地区约占全球市场份额的20%，印度和中国等国处于领先地位。监管机构对抗真菌治疗的支持力度不断增强，预计将在未来几年进一步推动市场增长。 印度正在成为市场的关键参与者，当地制造商如Zydus Cadila正在扩大其产品供应。竞争格局正在演变，跨国公司和地区参与者都在努力争夺市场份额。城市地区真菌感染的日益普遍也推动了对环吡酮市场产品需求的上升，使其成为未来投资的重点。 ### 中东和非洲：未开发的市场机会 中东和非洲地区逐渐成为环吡酮市场的一个市场，约占全球市场份额的5%。增长主要受到医疗保健可及性提高和对皮肤病状况认识增加的推动。监管框架正在不断演变，预计将促进新环吡酮市场配方的推出。 南非和阿联酋等国在市场发展方面处于领先地位。竞争格局由地方和国际参与者混合组成，Perrigo Company plc和Sandoz International GmbH等公司正在取得显著进展。该地区多样化的人口和不同的医疗需求为量身定制的环吡酮市场产品提供了独特的机会，使其成为未来投资的一个有吸引力的市场。 ## Competitive Benchmarking 环吡酮市场行业的主要参与者不断进行研究和开发，以增强其产品供应并获得竞争优势。领先的环吡酮市场参与者专注于开发满足客户不断变化需求的创新产品。 环吡酮市场的发展包括新产品的推出、现有产品线的扩展以及对其他公司的收购。预计在预测期内，环吡酮市场的竞争格局将保持动态，主要参与者将继续在产品质量、创新和成本效益等因素上竞争。 全球环吡酮市场的领先公司是博思健康公司（Bausch Health Companies Inc.）。该公司强大的品牌认知度、广泛的分销网络以及对研究和开发的关注为其在市场上的成功做出了贡献。 博思健康公司提供一系列环吡酮市场产品，包括外用溶液、乳膏和软膏。该公司的产品以多种品牌名称进行营销，如Loprox和Penlac。博思健康公司在北美和欧洲拥有强大的市场存在，并且该公司也在扩大其在新兴市场的影响力。 全球环吡酮市场的另一个主要参与者是塔罗制药工业有限公司（Taro Pharmaceutical Industries Ltd.）。该公司的优势包括其低成本的制造能力、强大的产品组合和广泛的分销网络。 塔罗制药工业有限公司提供一系列环吡酮市场产品，包括外用溶液、乳膏和软膏。该公司的产品以多种品牌名称进行营销，如Ciclodan和Ciclopirox Market-T。塔罗制药工业有限公司在北美和欧洲拥有强大的市场存在，并且该公司也在扩大其在新兴市场的影响力。 ## Recent News & Developments _真菌感染的日益普遍、对环吡酮市场的认识提高以及新产品的推出是推动市场增长的关键因素。_ _最近的发展包括2023年Luzu的局部环吡酮市场解决方案获得批准，用于治疗甲癣，以及2022年Hikma制药收购Taro制药，增强了Hikma在抗真菌市场的地位。_ _由于对有效抗真菌治疗的需求不断增加以及新配方和给药系统的发展，预计市场将继续增长。_ ## Report Scope | 2024年市场规模 | 0.4847（十亿美元） | | --- | --- | | 2025年市场规模 | 0.5084（十亿美元） | | 2035年市场规模 | 0.8197（十亿美元） | | 复合年增长率（CAGR） | 4.89%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 关键公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 关键市场机会 | 对抗真菌治疗的需求增长推动了Ciclopirox市场的创新。 | | 关键市场动态 | 对抗真菌治疗的需求上升推动了Ciclopirox市场的竞争和创新。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 到2035年，Ciclopirox市场的预计市场估值是多少？** A: 到2035年，Ciclopirox市场预计将达到8.197亿美元的估值。 **Q: 2024年Ciclopirox市场的市场估值是多少？** A: 2024年，Ciclopirox市场的价值为4.847亿美元。 **Q: 在2025年至2035年的预测期内，Ciclopirox市场的预期CAGR是多少？** A: 在2025年至2035年的预测期内，Ciclopirox市场的预期CAGR为4.89%。 **Q: 在Ciclopirox市场中，哪些公司被视为关键参与者？** A: Ciclopirox市场的主要参与者包括拜耳公司、Galderma S.A.、Mylan N.V.和Teva制药工业有限公司。 **Q: Ciclopirox的主要应用及其市场价值是什么？** A: 主要应用包括足癣和甲癣，估计价值约为1.45亿至2.48亿美元。 **Q: Ciclopirox市场上有哪些类型的药物制剂？** A: 可用的药物制剂包括乳膏、凝胶和指甲油，市场价值范围从0.085到0.205亿美元。 **Q: Ciclopirox 产品使用哪些给药途径？** A: 环吡酮产品以外用和口服的方式给药，外用形式的市场价值为2.9亿至4.9亿美元。 **Q: 股癣市场与其他股癣应用相比如何？** A: 股癣市场的估值在0.0725到0.1253亿美元之间，表明与足癣相比，这是一个较小的细分市场。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/ciclopirox-market-30191*